Tanvex BioPharma, Inc. (TPE:6541)
Taiwan · Delayed Price · Currency is TWD 36.75
-1.05 (-2.78%)
Jul 30, 2026, 11:24 AM CST
Tanvex BioPharma Market Cap
Tanvex BioPharma has a market cap or net worth of 10.02 billion as of July 29, 2026. Its market cap has decreased by -20.60% in one year.
Market Cap
10.02B
Enterprise Value
11.25B
Revenue
483.94M
Ranking
n/a
PE Ratio
n/a
Stock Price
36.75
ChartMarket Cap Chart
Since August 13, 2015, Tanvex BioPharma's market cap has decreased from 16.77B to 10.02B, a decrease of -40.27%. That is a compound annual growth rate of -4.59%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 29, 2026 | 10.02B | -31.23% |
| Dec 31, 2025 | 14.56B | 36.15% |
| Dec 31, 2024 | 10.70B | 22.75% |
| Dec 29, 2023 | 8.71B | -29.59% |
| Dec 30, 2022 | 12.38B | -39.56% |
| Dec 30, 2021 | 20.48B | 106.96% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Ever Supreme Bio Technology | 15.06B |
| EirGenix | 14.25B |
| ACRO Biomedical | 13.71B |
| TCM Biotech International | 13.17B |
| Polaris Group | 10.23B |
| Gongwin Biopharm Holdings | 10.19B |
| PharmaEngine | 9.45B |
| AP Biosciences | 9.16B |